Affordable Access

deepdyve-link
Publisher Website

Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.

Authors
  • Hoover, Rebecca M1
  • Erramouspe, John1
  • 1 1 Idaho State University, Pocatello, ID, USA.
Type
Published Article
Journal
Annals of Pharmacotherapy
Publisher
SAGE Publications
Publication Date
Mar 01, 2018
Volume
52
Issue
3
Pages
263–267
Identifiers
DOI: 10.1177/1060028017740139
PMID: 29094614
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To review and summarize topical oxymetazoline's pharmacology, pharmacokinetics, efficacy, safety, cost, and place in therapy for persistent redness associated with erythematotelangiectatic rosacea. Literature searches of MEDLINE (1975 to September 2017), International Pharmaceutical Abstracts (1975 to September 2017), and Cochrane Database (publications through September 2017) using the terms rosacea, persistent redness, α -agonist, and oxymetazoline. Results were limited to studies of human subjects, English-language publications, and topical use of oxymetazoline. Relevant materials from government sources, industry, and reviews were also included. Data support the efficacy of oxymetazoline for persistent facial redness. Little study beyond clinical trials cited in the drug approval process has been conducted. Current data suggest that oxymetazoline is similar in safety and efficacy to brimonidine. Head-to-head comparisons of topical α-agonists for erythema caused by rosacea are needed. The topical α-agonist, oxymetazoline, is safe and effective for reducing persistent facial redness associated with erythematotelangiectatic subtype of rosacea. Health care practitioners selecting among treatments should consider not only the subtype of rosacea but also individual patient response, preference, and cost.

Report this publication

Statistics

Seen <100 times